Sustained and NK/CD4+ T Cell-Dependent Efficient Prevention of Lung Metastasis Induced by Dendritic Cells Harboring Recombinant Sendai Virus1

@article{Komaru2009SustainedAN,
  title={Sustained and NK/CD4+ T Cell-Dependent Efficient Prevention of Lung Metastasis Induced by Dendritic Cells Harboring Recombinant Sendai Virus1},
  author={Atsushi Komaru and Yasuji Ueda and Aki Furuya and Sakura Tanaka and Kumi Yoshida and Tomonori Kato and Hiroaki Kinoh and Yui Harada and Hiroyoshi Suzuki and Makoto Inoue and Mamoru Hasegawa and Tomohiko Ichikawa and Yoshikazu Yonemitsu},
  journal={The Journal of Immunology},
  year={2009},
  volume={183},
  pages={4211 - 4219}
}
We recently demonstrated efficient antitumor immunity against murine tumors using dendritic cells (DCs) activated by recombinant Sendai viruses (rSeVs), and proposed a new concept, “immunostimulatory virotherapy,” for cancer immunotherapy. However, there has been little information on the efficacy of this method in preventing metastatic diseases. In this study, we investigated the efficacy of vaccinating DCs activated by fusion gene-deleted nontransmissible rSeV (rSeV/dF) using a murine model… 
RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer.
TLDR
The efficacy of vaccinating DCs activated by fusion gene-deleted nontransmissible rSeV on a rat model of lung metastasis using a highly malignant subline of Dunning R-3327 prostate cancer, AT6.3, indicates the essential role of RIG-I-independent signaling on antimetastatic effect induced by r SeV-activated DCs and may provide important insights to DC-based immunotherapy for advanced malignancies.
Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.
TLDR
The combination of radiation and rSeV/DC therapy induces different effector cells, depending on the time point during treatment, which causes the tumor to increase in size from an early stage of treatment in the CD4+ and NK cell-depleted group to increased in size during treatment with γ-irradiation.
IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells.
TLDR
It is suggested that induction of IFN I by VSV-ΔM51 allows DCs to overcome tumor-associated immunosuppression and facilitate IL-15-mediated priming of tumoricidal NK cells in tumor-bearing hosts.
Antagonism of VEGF by Genetically Engineered Dendritic Cells Is Essential to Induce Antitumor Immunity against Malignant Ascites
TLDR
It is determined that the imbalance between the VEGF-A/vascular permeability factor and its decoy receptor, soluble fms-like tryrosine kinase receptor-1 (sFLT-1), was a major cause of MA resistance to dendritic cell (DC)-based immunotherapy.
Title : Antagonism of VEGF by genetically engineered dendritic cells is essential to induce antitumor immunity against malignant ascitis
Malignant ascitis (MA) is a highly intractable and immunotherapy-resistant state of advanced gastrointestinal and ovarian cancers. Using a murine model of MA with CT26 colon cancer cells, we here
Dramatic improvement of DC-based immunotherapy against various malignancies.
TLDR
It is proved that DCs' antitumor effect depends on their number and the way they are activated, and a simple cytokine-based culture method is established to realize a log-scale order of functional murine/human DCs.
NK cells: key to success of DC-based cancer vaccines?
TLDR
It is underscore that the design of DC-based cancer vaccines should include the evaluation of their NK cell stimulating potency both in the preclinical phase and in clinical trials, and different strategies to improve DC vaccine preparations via exploitation of NK cells are discussed.
Prolonged Antitumor NK Cell Reactivity Elicited by CXCL10-Expressing Dendritic Cells Licensed by CD40L+CD4+ Memory T Cells
TLDR
It is demonstrated that long-term antitumor NK responses require endogenous DCs and a subset of effector memory CD4+ T (CD4- TEM) cells, suggesting that DC vaccination can sustain long- term innate NK cell immunity but requires the participation of the adaptive immune system.
Emerging role of Natural killer cells in oncolytic virotherapy
TLDR
The intrinsic immunostimulating capacity of oncolytic viruses and the possibility of engineering them to express heterologous Immunostimulatory molecules (eg, cytokines) support the use of these agents to enhance antitumor immune responses besides inducing direct on colytic effects.
Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination
TLDR
The observation that gemcitabine synergizes DCs mediated immunotherapy to improve the efficacy of large size lymphoma treatment provides an experimental basis for the combination of chemotherapy and immunotherapy for the efficient treatment of relapsed or refractory lymphoma.
...
1
2
3
4
...

References

SHOWING 1-10 OF 31 REFERENCES
Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation by Exogenous IFN-β Gene1
TLDR
Results indicate that rSeV is a new and powerful tool as an immune booster for DC-based cancer immunotherapy that can be significantly modified by IFN-β, and SeV/DC, therefore, warrants further investigation as a promising alternative for cancer Immunotherapy.
Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells.
TLDR
This is the first demonstration that non-transmissible SeV vector, SeV/dF, could be a DC-activator; DC/SeV/ dF-based cancer immunotherapy may, therefore, warrant further investigation.
CD4 cells can be more efficient at tumor rejection than CD8 cells.
TLDR
It is found that CD4 T cells can be powerful antitumor effector cells that can, in some cases, outperform CD8 T cells, which is the current "gold standard" effector cell in tumor immunotherapy.
CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
TLDR
It is shown that CD4+ T cells can eliminate IFN-γ-insensitive, MHC class II-negative cancer cells by an indirect mechanism that depends on IFn-γ.
CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.
TLDR
It is shown that an effective anti-tumor response involves communication between CD4+ T cells and nonhematopoietic cells, most likely within the tumor stroma, and that tumor immunity must not entirely rely on direct tumor cell killing.
Migration patterns of dendritic cells in the mouse. Traffic from the blood, and T cell-dependent and -independent entry to lymphoid tissues
TLDR
There is a spleen- liver equilibrium for DC, that may be akin to that existing between spleen and lymph node for T cells, according to the study of purified splenic DC and T lymphocytes in syngeneic and allogeneic mice.
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
TLDR
It is shown that expression of the NK cell receptor DNAM-1 is reduced on CD56(dim) NK cells from myeloma patients with active disease compared with patients in remission and healthy controls, suggesting that this receptor might play a role in NK-myeloma interactions.
The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46.
TLDR
It is established that the ability of NK p46 to recognize target cells is confined to the membrane proximal domain, and largely relies on the highly conserved sugar-carrying residue, Thr 225, which plays a critical dual role in NKp46 interactions with both viral hemagglutinins and the unknown tumor ligands via different mechanisms.
Complement function in mAb-mediated cancer immunotherapy.
TLDR
Using β-glucan as an adjuvant for mAb immunotherapy enables iC3b deposited on tumor cells by mAbs to activate complement receptor 3 (CR3) on effector cells, thus inducing CR3-dependent cellular cytotoxicity.
Functions of natural killer cells
TLDR
Although NK cells might appear to be redundant in several conditions of immune challenge in humans, NK cell manipulation seems to hold promise in efforts to improve hematopoietic and solid organ transplantation, promote antitumor immunotherapy and control inflammatory and autoimmune disorders.
...
1
2
3
4
...